Resveratrol: A potential challenger against gastric cancer
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (37) , 10636-43
Abstract
Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related mortality in the world. Late diagnosis and classical therapeutic approaches such as surgery, chemotherapy and radiotherapy make this disease a still threatening tumor. Genetic asset, environmental stress, dietary habit and infections caused by Helicobacter pylori (H. pylori) are the major causes concurring to GC initiation. A common mechanism is induction of radicals resulting in gastric mucosal injury. A regular food intake of antioxidant and radical scavenging agents has been proposed to exert protection against tumorigenesis. Resveratrol belongs to the polyphenol flavonoids class of antioxidants produced by a restricted number of plants. Resveratrol exerts bactericidal activity against H. pylori and is a powerful antioxidant, thus acting as a tumor preventive agent. Resveratrol intracellular signaling results in growth arrest and apoptosis, so that it can be directed against tumor progression. Resveratrol therapeutic potential against GC initiation and progression are reviewed here.Keywords
This publication has 84 references indexed in Scilit:
- Resveratrol Inhibits the Growth of Gastric Cancer by Inducing G1 Phase Arrest and Senescence in a Sirt1-Dependent MannerPLOS ONE, 2013
- Resveratrol: French Paradox RevisitedFrontiers in Pharmacology, 2012
- Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and PharmacodynamicsCancer Prevention Research, 2011
- Enhancing the bioavailability of resveratrol by combining it with piperineMolecular Nutrition & Food Research, 2011
- The Use of 3,5,4′-Tri-O-acetylresveratrol as a Potential Prodrug for Resveratrol Protects Mice from γ-Irradiation-Induced DeathACS Medicinal Chemistry Letters, 2011
- Cyclodextrin-Based Nanosponges for Delivery of Resveratrol: In Vitro Characterisation, Stability, Cytotoxicity and Permeation StudyAAPS PharmSciTech, 2011
- Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer PatientsCancer Research, 2010
- Recent patterns in gastric cancer: A global overviewInternational Journal of Cancer, 2009
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006